Pharmaceutical company, Moderna, Inc. (MRNA), Wednesday announced that the interim data on the company's mRNA-3927, an investigational mRNA therapy for propionic acidemia or PA, was published in Nature magazine.
PA is a rare, inherited metabolic disorder that results from the body's inability to process certain parts of proteins and lipids due to a specific enzyme deficiency.
During the trial to study the safety, pharmacodynamics, and pharmacokinetics of mRNA-3927 in participants aged one year and older with genetically confirmed PA, a 70 percent reduction in metabolic decompensation events was observed during the treatment period.
The company further said that the therapy has been reportedly well tolerated in trial participants, with no dose-limiting toxicities observed. However, fifteen participants reported treatment-emergent adverse events and eight participants reported serious adverse events which were unrelated to mRNA-3927.
Currently, Moderna's stock is gaining 0.22 percent, to $103.88 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.